ISA Pharmaceuticals is a privately held company based in the Netherlands. It focuses on the development of rationally designed, fully synthetic immunotherapeutics for the treatment of cancer and persistent viral infections. ISA’s development platform is based on its proprietary SLP® (synthetic long peptide) and AMPLIVANT® technologies. The platform is broadly applicable and suitable for a multitude of targets and product opportunities.
The company has established its development platform based on insight into the exact mechanism of action and the immunopharmacology of its immunotherapeutics. Various clinical trials up to completion of Phase II have demonstrated the safety, tolerability and clinical efficacy of SLP® compounds, thereby providing proof-of-concept.
The company was founded in 2004 by Aglaia Oncology Fund with Leiden University Medical Center (LUMC) as its primary research partner.
Showcase to 300+ investors and pharma at our 5th flagship LSX World Congress.
Plus save £500 before 14th December!
LSX, formerly Biotech and Money, is an influential community of senior life science decision makers. We connect senior life science executives with access to the capital, intelligence, innovation, and partners they need to grow their businesses.